

**Building strong digi-retail bank, but higher opex an irritant**BFSI - Banks ▶ Analyst Meet Update ▶ **November 24, 2023****TARGET PRICE (Rs): 1,300**

**Axis Bank hosted its analyst meet on 23-Nov, to give an update on its GPS (growth, profitability, stability) strategy and the way forward. Bank guides for some systemic growth moderation post the recent RBI action on unsecured/NBFC loans, albeit for own continued outperformance led by its retail+SME growth engine. Bank's margin is higher by 30bps at 4.1% vs its base guidance of 3.8%; it targets retaining some structural gains due to organic PSL build-up via Bharat Banking and a better portfolio mix, despite rising CoF. Asset quality is holding up well, with NNPA at 0.4% and no immediate sign of stress; but Bank guides for some LLP normalization and plans to uphold contingent provisions for now. However, it guides for an elevated opex, given retail/digital infra build-up causing a drag on RoA@1.8% (>1.9-2% for peers). We believe Bank needs to shore-up its CET 1 (2Q @14.6% vs large peers @>15%), more so post the impact (~50bps) from the recent RBI action; but it guided that it has no such plans, due to its effective capital management/higher RoE (17-18%; partly due to higher leverage). Valuations remain low at 1.6x FY25E ABV vs large peers' at >2x; thus, we retain BUY with TP of Rs1,300 (on 2x Sep-25E ABV; subs value of Rs83/sh).**

**AXIS Bank: Financial Snapshot (Standalone)**

Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Net profit	1,30,255	95,797	2,48,993	2,90,889	3,37,587
Loan growth (%)	15.2	19.4	17.5	16.7	18.1
NII growth (%)	13.3	29.6	16.5	13.9	14.1
NIM (%)	3.3	3.7	3.8	3.7	3.6
PPOP growth (%)	7.0	(20.0)	84.3	25.9	20.6
Adj. EPS (INR)	42.5	31.2	80.9	94.4	109.5
Adj. EPS growth (%)	89.7	(26.6)	159.4	16.7	16.1
Adj. BV (INR)	364.0	399.7	476.7	568.0	672.4
Adj. BVPS growth (%)	10.8	9.8	19.3	19.2	18.4
RoA (%)	1.2	0.8	1.8	1.8	1.8
RoE (%)	12.0	8.0	18.1	17.7	17.3
P/E (x)	23.5	32.1	12.4	10.6	9.1
P/ABV (x)	2.5	2.3	1.9	1.6	1.4

Source: Emkay Research

**Higher Retail, SME and Bharat Banking growth to help retain some margin gains**

Notwithstanding the potential impact of unsecured loan growth (incl. PL/Cards)—due to RBI action on unsecured/NBFC loans—on the systemic credit growth (as also for Axis Bank), Bank would continue to outperform, resulting in mkt-share gains led by healthy growth in its retail+SME segments, thereby delivering better RaRoC. Also, Bank would sustain focus on Bharat Banking (incl. MFI, gold, tractor loans, etc), which has led to self-sufficiency in PSL and thus helped reduce the RIDF portfolio (@2.1% from the 5.1% high) and the margin drag. With organic MFI build-up being healthy at Rs60bn without much support from BCs, Bank does not see immediate need for any inorganic acquisition. Incrementally, it plans to accelerate liability mobilization from RuSu (Rural-Semi urban) branches, thereby bringing more stability to its liability profile. Though its LCR remains moderate at 118%, the bank claims that there has been a 550bps reduction in outflow rate in the past 2 years; this underscores its commitment to improve the quality of LCR. Bank reported stable margin in 2Q at 4.1% (which is higher by 30bps from its base guidance of 3.8%) and could see some moderation amid rising CoF. However, Bank targets retaining some gains due to structural improvement, incl. organic PSL build-up via Bharat Banking and improving portfolio mix (retail+SME @69% vs 62% in FY20).

**Credit cost to remain soft, but opex to be elevated amid retail/digital infra build-up**

Axis Bank has one of the lowest NNPA/retail-NNPA ratios among peers, at 0.4%/0.5%, while its unsecured share is 11% of loans. Given strong PCR on the back book and no immediate sign of asset quality risk, Bank expects credit cost to normalize from current lows, albeit remain soft in the near/medium term. Bank carries contingent provision buffer at ~0.5% of loans and would take a call on reclassifying its Covid buffer or reducing it/shoring it up by year-end. But it guides for an elevated near-term opex, which should gradually moderate to 2% of assets (looks optimistic) as the Citi acquisition drag and heavy infra/digital build-up costs reduce. Further, attrition remains high for AxisB, as also for peers, thus leading to higher cost; but it has taken multiple course corrections—higher employee engagement, pay raises, even offering a better lateral opportunity within the bank—to arrest attrition in key divisions,. Moreover, it believes fee/asset ratio could further improve, led by Cards and neo-initiatives on Wholesale.

**We retain BUY**


We expect the bank to clock healthy RoA of 1.8% (though lower than peers' at ≥2%) from a low of 0.8% in FY23, while reporting healthy RoE of 17-18% (partly inflated due to the Citi acquisition goodwill w-off) over FY24-26E, on merged basis. However, Bank needs to shore-up its CET 1 (2Q @14.5% vs large peers' @>15%), more so post the recent RBI action on unsecured loans. At the CMP, valuations remain reasonable vs peers at 1.6x FY25E ABV. Thus, we retain BUY, with TP of Rs1,300/sh, based on 2x Sep-25E ABV and subs value of Rs83/sh. Key risks: Macro-dislocation leading to slower growth/higher NPAs and KMP attrition.

Target Price – 12M	Sep-24
<b>Change in TP (%)</b>	<b>NA</b>
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	30.1
CMP (23-Nov-23) (Rs)	999.1

Stock Data	Ticker
52-week High (Rs)	1,048
52-week Low (Rs)	814
Shares outstanding (mn)	3,082.5
Market-cap (Rs bn)	3,080
Market-cap (USD mn)	36,951
Net-debt, FY24E (Rs mn)	NA
ADTV-3M (mn shares)	9
ADTV-3M (Rs mn)	8,694.8
ADTV-3M (USD mn)	104.3
Free float (%)	89.0
Nifty-50	19,802
INR/USD	83.3
<b>Shareholding, Sep-23</b>	
Promoters (%)	8.0
FPIs/MFs (%)	51.2/28.1

**Price Performance**

(%)	1M	3M	12M
Absolute	3.6	2.0	14.2
Rel. to Nifty	0.9	0.2	5.4

**1-Year share price trend (Rs)****Anand Dama**

anand.dama@emkayglobal.com  
+91 22 6624 2480

**Kunaal N**


kunaal.n@emkayglobal.com  
+91 22 6612 1275

**Marazbaan Dastur**

marazbaan.dastur@emkayglobal.com  
+91 22 6612 1281


# Story in Charts

**Exhibit 1: Axis Bank continues to gain credit/deposit market share...**




Source: Company, Emkay Research

**Exhibit 2: ...as also in CASA, leading to contained CoF**




Source: Company, Emkay Research

**Exhibit 3: Axis Bank has relatively better CASA ratio vs some peers, but slightly higher CoF...**




Source: Emkay Research

**Exhibit 4: ...which reflects in its comparatively lower albeit stable NIM**




Source: Emkay Research

**Exhibit 5: Opex/Assets for Axis Bank should remain elevated due to retail/digital infra build-up**




Source: Emkay Research

**Exhibit 6: Axis Bank to focus on improving its fee income, partly offsetting its higher opex**




Source: Emkay Research; Note: HDFCB's FY23 fee/assets are for the standalone bank vs merged for FY26E

**Exhibit 7: Axis Bank has one of the lowest NNPA among peers (ex-HDFCB)**




Source: Emkay Research

**Exhibit 8: LLP should normalize, yet remain well-contained, given the strong PCR, contingent buffer**




Source: Company, Emkay Research

**Exhibit 9: Axis Bank, IIB see sharp reduction in RWA/Assets and, hence, capital burn**



Source: Emkay Research

**Exhibit 10: Lower CET 1 accretion for Axis Bank/HDFCB due to acquisition of the Citi portfolio/HDFCL, respectively**




Source: Emkay Research

**Exhibit 11: Axis Bank could see a ~50bps impact, leading to further reduction in its CET 1**


**Exhibit 12: CET 1, post the impact from the increased RWA on Unsecured loans/NBFC exposure, for Axis Bank could be low at 14% vs >15% for peers**

Impact on CET 1 due to increased RWA on UL/NBFC loans (bps)



Source: Emkay Research

CET 1 % (2QFY24) vs CET 1 % post Impact on UL/NBFC loans




Source: Emkay Research

**Exhibit 13: Axis Bank has seen improvement in RoA, which would though remain lower than peers' due to lower NIM, higher opex...**


**Exhibit 14: ...but has higher RoE due to higher leverage, which should further moderate, as the bank raises capital**

RoA (%)



Source: Emkay Research

RoE (%)




Source: Emkay Research

**Exhibit 15: Axis Bank remains one of the cheapest large PVBs**


**Exhibit 16: Bank continues to trade at below mean valuations**

P/ABV(x)



Source: Emkay Research

P/AdjBVPS (x), Mean, +2 SD, -2 SD



Source: Bloomberg, Emkay Research

## AXIS Bank: Standalone Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Interest Income	6,73,768	8,51,638	11,01,219	12,36,806	13,93,995
Interest Expense	3,42,446	4,22,180	6,00,976	6,67,129	7,44,072
<b>Net interest income</b>	<b>3,31,322</b>	<b>4,29,457</b>	<b>5,00,243</b>	<b>5,69,678</b>	<b>6,49,923</b>
NII growth (%)	13.3	29.6	16.5	13.9	14.1
Other income	1,52,205	1,65,009	2,13,596	2,61,801	3,19,422
<b>Total Income</b>	<b>4,83,528</b>	<b>5,94,466</b>	<b>7,13,838</b>	<b>8,31,479</b>	<b>9,69,345</b>
Operating expenses	2,36,108	3,96,560	3,49,107	3,72,225	4,15,603
<b>PPOP</b>	<b>2,47,420</b>	<b>1,97,906</b>	<b>3,64,731</b>	<b>4,59,254</b>	<b>5,53,742</b>
PPOP growth (%)	7.0	(20.0)	84.3	25.9	20.6
<b>Core PPOP</b>	<b>2,33,643</b>	<b>2,00,657</b>	<b>3,55,114</b>	<b>4,47,715</b>	<b>5,41,048</b>
Provisions & contingencies	73,595	28,848	31,757	70,345	1,02,485
<b>PBT</b>	<b>1,73,826</b>	<b>1,69,059</b>	<b>3,32,974</b>	<b>3,88,910</b>	<b>4,51,257</b>
Extraordinary items	0	0	0	0	0
Tax expense	43,571	73,262	83,981	98,021	1,13,670
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
<b>Reported PAT</b>	<b>1,30,255</b>	<b>95,797</b>	<b>2,48,993</b>	<b>2,90,889</b>	<b>3,37,587</b>
PAT growth (%)	97.7	(26.5)	159.9	16.8	16.1
<b>Adjusted PAT</b>	<b>1,30,255</b>	<b>95,797</b>	<b>2,48,993</b>	<b>2,90,889</b>	<b>3,37,587</b>
<b>Diluted EPS (INR)</b>	<b>45.9</b>	<b>31.1</b>	<b>80.6</b>	<b>94.1</b>	<b>109.2</b>
Diluted EPS growth (%)	90.3	(32.3)	159.4	16.7	16.1
<b>DPS (INR)</b>	<b>1.0</b>	<b>1.0</b>	<b>1.6</b>	<b>2.2</b>	<b>2.8</b>
<b>Dividend payout (%)</b>	<b>2.4</b>	<b>3.2</b>	<b>2.0</b>	<b>2.3</b>	<b>2.6</b>
Effective tax rate (%)	25.1	43.3	25.2	25.2	25.2
Net interest margins (%)	3.3	3.7	3.8	3.7	3.6
Cost-income ratio (%)	48.8	66.7	48.9	44.8	42.9
Shares outstanding (mn)	3,069.7	3,076.9	3,081.8	3,081.8	3,081.8

Source: Company, Emkay Research

Asset quality and other metrics					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
<b>Asset quality</b>					
Gross NPLs	1,85,655.6	1,70,190.2	1,55,619.3	1,52,107.2	1,74,210.0
Net NPLs	47,452.3	34,390.4	40,461.0	42,590.0	52,263.0
GNPA ratio (%)	2.6	2.0	1.5	1.3	1.3
NNPA ratio (%)	0.7	0.4	0.4	0.4	0.4
Provision coverage (%)	74.4	79.8	74.0	72.0	70.0
Gross slippages	1,89,156.8	1,42,535.8	1,45,709.5	1,75,605.0	2,21,028.2
Gross slippage ratio (%)	2.6	1.7	1.5	1.5	1.6
LLP ratio (%)	0.9	0.4	0.5	0.7	0.8
NNPA to networth (%)	3.9	2.6	2.5	2.3	2.3
<b>Capital adequacy</b>					
Total CAR (%)	18.5	17.6	16.6	16.5	16.2
Tier-1 (%)	16.3	14.6	14.5	14.6	14.5
CET-1 (%)	15.2	14.1	14.1	14.3	14.3
RWA-to-Total Assets (%)	61.0	68.3	72.6	74.2	75.7
<b>Miscellaneous</b>					
Total income growth (%)	9.2	23.1	29.3	14.0	14.3
Opex growth (%)	28.5	68.0	(12.0)	6.6	11.7
Core PPOP growth (%)	5.5	(14.1)	77.0	26.1	20.8
PPOP margin (%)	30.0	19.5	27.7	30.6	32.3
PAT/PPOP (%)	52.6	48.4	68.3	63.3	61.0
LLP-to-Core PPOP (%)	31.5	14.4	8.9	15.7	18.9
Yield on advances (%)	7.6	8.4	9.6	9.2	8.9
Cost of funds (%)	3.7	3.9	5.0	4.8	4.5

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	6,139	6,154	6,164	6,164	6,164
Reserves & surplus	11,45,600	12,48,013	14,92,075	17,76,184	21,05,142
<b>Net worth</b>	<b>11,51,740</b>	<b>12,54,167</b>	<b>14,98,239</b>	<b>17,82,348</b>	<b>21,11,306</b>
Deposits	82,19,715	94,69,452	1,09,26,243	1,28,36,207	1,53,11,590
Borrowings	18,51,339	18,63,000	19,78,206	22,56,125	25,74,791
<b>Interest bearing liab.</b>	<b>1,00,71,054</b>	<b>1,13,32,452</b>	<b>1,29,04,449</b>	<b>1,50,92,332</b>	<b>1,78,86,381</b>
<b>Other liabilities &amp; prov.</b>	<b>5,31,495</b>	<b>5,86,636</b>	<b>6,69,235</b>	<b>6,36,050</b>	<b>5,97,673</b>
<b>Total liabilities &amp; equity</b>	<b>1,17,54,288</b>	<b>1,31,73,255</b>	<b>1,50,71,922</b>	<b>1,75,10,730</b>	<b>2,05,95,361</b>
Net advances	70,79,466	84,53,028	99,33,771	1,15,97,485	1,36,92,316
Investments	27,55,972	28,88,148	32,59,100	37,79,426	43,75,586
Cash, other balances	11,09,871	10,64,108	10,32,356	11,31,925	13,41,479
<b>Interest earning assets</b>	<b>1,09,45,309</b>	<b>1,24,05,285</b>	<b>1,42,25,227</b>	<b>1,65,08,836</b>	<b>1,94,09,380</b>
Fixed assets	45,724	47,339	99,157	1,10,301	1,22,735
Other assets	7,63,255	7,20,632	7,47,538	8,91,593	10,63,246
<b>Total assets</b>	<b>1,17,54,288</b>	<b>1,31,73,255</b>	<b>1,50,71,922</b>	<b>1,75,10,730</b>	<b>2,05,95,361</b>
BVPS (INR)	375.6	408.1	486.6	578.4	685.1
Adj. BVPS (INR)	364.0	399.7	476.7	568.0	672.4
Gross advances	72,17,669	85,88,828	1,00,48,929	1,17,07,002	1,38,14,263
Credit to deposit (%)	86.1	89.3	90.9	90.3	89.4
CASA ratio (%)	45.0	47.2	45.5	43.9	43.5
Cost of deposits (%)	3.5	3.6	4.7	4.6	4.4
Loans-to-Assets (%)	60.2	64.2	65.9	66.2	66.5
Net advances growth (%)	15.2	19.4	17.5	16.7	18.1
Deposit growth (%)	17.8	15.2	15.4	17.5	19.3
Book value growth (%)	8.8	8.7	19.2	18.9	18.5

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY22	FY23	FY24E	FY25E	FY26E
P/E (x)	21.4	29.2	11.3	9.6	8.3
P/B (x)	2.4	2.2	1.9	1.6	1.3
P/ABV (x)	2.5	2.3	1.9	1.6	1.4
P/PPOP (x)	12.3	15.4	8.4	6.6	5.5
Dividend yield (%)	0.1	0.1	0.2	0.2	0.3
<b>DuPont-RoE split (%)</b>					
NII/avg assets	3.1	3.4	3.5	3.5	3.4
Other income	1.4	1.3	1.5	1.6	1.7
Fee income	1.1	1.2	1.2	1.3	1.4
Opex	2.2	3.2	2.5	2.3	2.2
<b>PPOP</b>	<b>2.3</b>	<b>1.6</b>	<b>2.6</b>	<b>2.8</b>	<b>2.9</b>
Core PPOP	2.2	1.6	2.5	2.7	2.8
Provisions	0.7	0.2	0.2	0.4	0.5
Tax expense	0.4	0.6	0.6	0.6	0.6
<b>RoA (%)</b>	<b>1.2</b>	<b>0.8</b>	<b>1.8</b>	<b>1.8</b>	<b>1.8</b>
Leverage ratio (x)	10.0	10.4	10.3	9.9	9.8
<b>RoE (%)</b>	<b>12.0</b>	<b>8.0</b>	<b>18.1</b>	<b>17.7</b>	<b>17.3</b>
<b>Quarterly data</b>					
Rs mn, Y/E Mar	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24E
NII	1,03,603	1,14,593	1,17,422	1,19,588	1,23,146
NIM (%)	4.0	4.3	4.2	4.1	4.1
PPOP	77,162	92,775	91,676	88,144	86,319
PAT	53,298	58,531	67,614	57,971	58,636
EPS (Rs)	17.35	19.03	21.98	18.82	19.04


Source: Company, Emkay Research

**RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
25-Oct-23	955	1,300	Buy	Anand Dama
26-Jul-23	977	1,260	Buy	Anand Dama
28-Apr-23	860	1,225	Buy	Anand Dama
09-Mar-23	868	1,250	Buy	Anand Dama
02-Mar-23	845	1,250	Buy	Anand Dama
23-Jan-23	933	1,300	Buy	Anand Dama
25-Nov-22	888	1,110	Buy	Anand Dama
21-Oct-22	900	1,110	Buy	Anand Dama
25-Jul-22	727	1,020	Buy	Anand Dama
29-Apr-22	729	1,020	Buy	Anand Dama
31-Mar-22	761	1,020	Buy	Anand Dama
25-Jan-22	752	1,020	Buy	Anand Dama
27-Oct-21	788	1,020	Buy	Anand Dama
27-Jul-21	732	960	Buy	Anand Dama
18-Jun-21	736	960	Buy	Anand Dama
28-Apr-21	708	850	Buy	Anand Dama
28-Jan-21	671	850	Buy	Anand Dama
20-Jan-21	676	850	Buy	Anand Dama

Source: Company, Emkay Research

**RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

**GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com).

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

**RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons<sup>1</sup> may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm’s length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative’s may have Financial Interest/proprietary positions in the securities recommended in this report as of November 24, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report  
**Disclosure of previous investment recommendation produced:**
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative’s may have material conflict of interest in the securities recommended in this report as of November 24, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative’s may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the November 24, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

**Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
<b>BUY</b>	Over 15%
<b>HOLD</b>	Between -5% to 15%
<b>SELL</b>	Below -5%

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

**OTHER DISCLAIMERS AND DISCLOSURES:****Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.